Investigational Drug Information for Amibegron
✉ Email this page to a colleague
What is the development status for investigational drug Amibegron?
Amibegron is an investigational drug.
There have been 4 clinical trials for Amibegron.
The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2003.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Sanofi and [disabled in preview].
Summary for Amibegron
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 80 |
| WIPO Patent Applications | 65 |
| Japanese Patent Applications | 41 |
| Clinical Trial Progress | Phase 3 (2003-11-01) |
| Vendors | 10 |
Recent Clinical Trials for Amibegron
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy and Safety of SR58611A in Patients With Major Depressive Disorder (SIRIUS) | Sanofi | Phase 3 |
| Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder | Sanofi | Phase 3 |
| Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine | Sanofi | Phase 3 |
Clinical Trial Summary for Amibegron
Top disease conditions for Amibegron
Top clinical trial sponsors for Amibegron
US Patents for Amibegron
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
